v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating activities    
Net Income (Loss) $ (12,518,480) $ (5,575,777)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation, amortization and impairment 7,151 4,424
Equity-based compensation 219,058 273,730
Change in fair value of warrant liability (6,540) 0
In-process research and development expense 8,517,966 0
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 419,628 492,471
Accounts payable (1,167,068) 334,141
Accrued expenses (298,903) (54,326)
Net cash used in operating activities (4,827,188) (4,525,337)
Investing activities    
Issuance of promissory loan in connection with asset acquisition (577,000) 0
Cash received from asset acquisition, net of cash paid 1,341,735 0
Net cash provided by investing activities 764,735 0
Financing activities    
Proceeds from issuance of equity securities, net 12,559,728 1,526,460
Payments on note payable (221,866) (466,505)
Net cash provided by financing activities 12,337,862 1,059,955
Net increase (decrease) in cash, cash equivalents , and restricted cash 8,275,409 (3,465,382)
Cash, cash equivalents and restricted cash at beginning of period 2,434,528 5,899,910
Cash, cash equivalents and restricted cash at end of period 10,709,937 2,434,528
Supplemental disclosure of cash flow information:    
Cash paid for interest 5,800 10,643
Preferred stock issued for in-process research and development technology 4,302,000 0
Accrued issuance costs for public offering 185,032 0
Settlement of promissory loans in connection with asset acquisition 577,000 0
Prepaid expense financed by note payable $ 0 $ 398,728